 REDWOOD CITY, Calif., Dec. 02, 2021 GLOBE NEWSWIRE -- Bolt Biotherapeutics, Inc. Nasdaq: BOLT, a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that the company will be presenting interim clinical data in a virtual poster on BDC-1001, starting on December 6, 2021 in conjunction with the European Society for Medical Oncology Immuno-Oncology ESMO I-O Congress 2021 taking place on December 8 - 11, 2021. BDC-1001 is an immune-stimulating antibody conjugate ISAC comprising a HER2-targeting biosimilar of trastuzumab conjugated to a TLR78 agonist with a non-cleavable linker. 